First patient dosed in IST of CDK inhibitor Seliciclib in Cushing's disease

Cyclacel Pharmaceuticals, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the first patient has been dosed in an investigator sponsored trial (IST) of the Company's oral cyclin dependent kinase (CDK) inhibitor seliciclib in Cushing's disease.

Press Release